At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
EYPT EyePoint
Pre-Market Trading 12-23 09:01:50 EST
7.10
-0.02
-0.28%
盘前7.38
+0.28+3.94%
08:23 EST
High7.42
Low6.90
Vol4.16M
Open6.96
D1 Closing7.12
Amplitude7.30%
Mkt Cap498.14M
Tradable Cap358.49M
Total Shares70.16M
T/O29.63M
T/O Rate8.24%
Tradable Shares50.49M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
EyePoint reports inducement grants under NASDAQ listing rule
EyePoint Announces First Patient Dosed in Second Global Phase 3 Lucia Clinical Trial of Duravyu™ for the Treatment of Wet Age-Related Macular Degeneration
EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.